Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Pneumococcal Vaccination in the Elderly Needs Government Support
September 25, 2006
- Kowa Pharmaceutical Aims for Sales of \74.8 Bil. in FY2007
September 25, 2006
- R&D NEWS IN BRIEF
September 25, 2006
- Once-weekly Osteoporosis Drug Both Effective and Convenient
September 25, 2006
- Dr Bale Discusses Current Top Priorities at IFPMA
September 25, 2006
- Korosho to Promote Domestic Vaccine Development, Blood Donation
September 25, 2006
- Aging, Vitamin C Deficiency Contribute to COPD
September 25, 2006
- Global Partnerships Essential in BT Industry: Dr Mimura
September 25, 2006
- Online Processing of Medical Bills to Expand in April 2007
September 25, 2006
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 25, 2006
- JETRO BIOLINK FORUM 2006:Importance of Alliances Stressed
September 25, 2006
- NWE PRODUCTS
September 25, 2006
- BUSINESS NEWS IN BRIEF
September 25, 2006
- Sekisui Chemical to Acquire Daiichi Pure Chemicals
September 25, 2006
- Sawai to Reorganize Its Hansha by Region
September 25, 2006
- Daiichi Sankyo to Transfer All Shares of DRL to Fuji Film
September 25, 2006
- TOPICS Janssen-Cilag, Ortho Biotech Receive 2006 Prix Galien for Velcade
September 25, 2006
- MEDICAL DEVICE NEWS IN BRIEF
September 25, 2006
- Daiko to Focus on R&D Due to Difficulty in Making All Strengths Available
September 25, 2006
- Kobayashi Pharm. Announces 3-Pronged Management Strategy
September 25, 2006
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…